Research Article
Association between High-Density Lipoprotein Cholesterol to Apolipoprotein A-I Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study
Table 1
Comparison of clinical characteristics between the participants with and without NAFLD.
| | Variables | With NAFLD (n = 3038) | Without NAFLD (n = 5987) | Z value | value |
| | Age (year) | 52 (43–63) | 49 (39–62) | −7.577 | <0.001 | | Gender (male/female, n) | 2389/649 | 3842/2145 | 197.283† | <0.001 | | Body mass index (kg/m2) | 25.10 (23.53–27.00) | 22.00 (20.40–23.70) | −49.467 | <0.001 | | Waist circumference (cm) | 89 (85–94) | 80 (74–86) | −44.467 | <0.001 | | Systolic blood pressure (mmHg) | 132 (122–142) | 124 (113–135) | −22.649 | <0.001 | | Diastolic blood pressure (mmHg) | 80 (72–87) | 73 (66–81) | −24.292 | <0.001 | | Alanine aminotransferase (U/L) | 26 (19–40) | 17 (13–23) | −38.158 | <0.001 | | Aspartate aminotransferase (U/L) | 23 (19–29) | 20 (17–25) | −21.456 | <0.001 | | γ-Glutamyl transferase (U/L) | 32 (23–50) | 20 (15–28) | −37.811 | <0.001 | | Triglyceride (mmol/L) | 1.83 (1.34–2.56) | 1.13 (0.85–1.56) | −40.646 | <0.001 | | Total cholesterol (mmol/L) | 4.99 (4.38–5.65) | 4.71 (4.14–5.35) | −12.828 | <0.001 | | HDL-C (mmol/L) | 1.19 (1.03–1.35) | 1.31 (1.15–1.49) | −21.573 | <0.001 | | LDL-C (mmol/L) | 2.82 (2.34–3.33) | 2.74 (2.31–3.22) | −4.408 | <0.001 | | Apo A-I (mmol/L) | 1.18 (1.05–1.32) | 1.27 (1.12–1.46) | −18.130 | <0.001 | | Fasting plasma glucose (mmol/L) | 5.42 (5.05–5.97) | 5.18 (4.91–5.54) | −18.705 | <0.001 | | Serum uric acid (μmol/L) | 382 (329–434) | 328 (276–380) | −28.709 | <0.001 | | HbA1c (%) | 5.50 (5.20–5.90) | 5.30 (5.10–5.60) | −21.146 | <0.001 | | HDL-C/apo A-I | 1.00 (0.88–1.13) | 1.02 (0.91–1.13) | −5.207 | <0.001 |
|
|
Data are presented as median (IQR) due to skewed distribution. †χ2 value; apo A-I, apolipoprotein A-I; HbA1c, glycated hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HDL-C/apo A-I, high-density lipoprotein cholesterol to apolipoprotein A-I ratio; LDL-C, low-density lipoprotein cholesterol; NAFLD, nonalcoholic fatty liver disease.
|
